Hypogammaglobulinemia after heart transplantation: impact of pre‐emptive use of immunoglobulin replacement (CytoGam®) on infection and rejection outcomes
Authors:
- 1 December 2001
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 3 (s2) , 40-43
Abstract
Hypogammaglobulinemia (HGG) in solid organ transplant (SOT) patients confers an increased risk of opportunistic infections and poorer outcomes. Severe HGG (IgG < 350 mg/dL) after heart transplantation may follow intensification of immunosuppressive therapy and the resultant increased risk of opportunistic infections, particularly cytomegalovirus (CMV) disease. Evaluation of the effects of replacement therapy using intravenous immunoglobulin (CMV‐IGIV, CytoGam®) was conducted in cardiac transplant recipients and the data matched with a historical control group. Patients with severe HGG who received pre‐emptive replacement therapy had significantly fewer opportunistic infections (P < 0.001) and episodes of rejection (grade 3; P = 0.03 and grade 2; P = 0.04) compared with the control group.Keywords
This publication has 4 references indexed in Scilit:
- Hypogammaglobulinemia following cardiac transplantation: a link between rejection and infectionThe Journal of Heart and Lung Transplantation, 2001
- HYPOGAMMAGLOBULINEMIA IN LUNG TRANSPLANT RECIPIENTSTransplantation, 2001
- Significant post‐transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon?Transplant Infectious Disease, 2000
- INFECTION IN THE ORGAN TRANSPLANT RECIPIENTInfectious Disease Clinics of North America, 1995